Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$126.72

-1.14 (-0.89%)

(As of 07/26/2024 ET)

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 8 Analyst Ratings

Based on 8 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 2 have given a hold rating, and 6 have given a buy rating for NVO.

Consensus Price Target

$145.67
14.95% Upside

High Forecast	$163.00
Average Forecast	$145.67
Low Forecast	$115.00

According to the 8 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $145.67. The highest price target for NVO is $163.00, while the lowest price target for NVO is $115.00. The average price target represents a forecasted upside of 14.95% from the current price of $126.72.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	3 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$145.67	$145.67	$133.60	$36.25
Forecasted Upside	14.95% Upside	13.79% Upside	22.63% Upside	12.21% Upside

Get Novo Nordisk A/S Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Ad Stansberry Research

Get out of cash before the Fed's next meeting

"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."

Click here now to watch this exclusive interview

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	14.94% Upside	2,841.29% Upside	9.13% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/1/2024	Cantor Fitzgerald 3 of 5 stars	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $160.00	+10.31%
6/25/2024	BMO Capital Markets 3 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$163.00 ➝ $163.00	+11.27%
6/10/2024	Argus 2 of 5 stars		Boost Target	Buy ➝ Buy	$125.00 ➝ $160.00	+13.09%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$156.00	+17.58%
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$120.00	+13.75%
1/16/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral
Get the Latest News and Ratings for NVO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.
12/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$105.00 ➝ $115.00	+14.19%
8/11/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
4/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform
12/12/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$32.50 ➝ $36.25	+11.94%
9/29/2022	Oddo Bhf Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:55 AM ET.

NVO Forecast - Frequently Asked Questions

What is Novo Nordisk A/S's forecast for 2024?: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $145.67, with a high forecast of $163.00 and a low forecast of $115.00.
Should I buy or sell Novo Nordisk A/S stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVO shares.
Does Novo Nordisk A/S's stock price have much upside?: According to analysts, Novo Nordisk A/S's stock has a predicted upside of 13.23% based on their 12-month stock forecasts.
What analysts cover Novo Nordisk A/S?: Novo Nordisk A/S has been rated by research analysts at Argus, BMO Capital Markets, Cantor Fitzgerald, and The Goldman Sachs Group in the past 90 days.
Do Wall Street analysts like Novo Nordisk A/S more than its competitors?: Analysts like Novo Nordisk A/S more than other "medical" companies. The consensus rating score for Novo Nordisk A/S is 2.75 while the average consensus rating score for "medical" companies is 2.72. Learn more on how NVO compares to other companies.